The global lung cancer therapeutics market size reached US$ 27,221.60 Million in 2022. Looking forward, the publisher expects the market to reach US$ 50,233 Million by 2028, exhibiting a growth rate (CAGR) of 10.90% during 2023-2028. The rising prevalence of lung cancer due to unhealthy lifestyles and excessive smoking, increasing awareness among individuals about the importance of early diagnosis and treatment, and advancements in precision medicine represent some of the key factors driving the market.
Lung cancer therapeutics refer to various treatment options used for managing and treating the symptoms of lung cancer, which include shortness of breath, chest pain, wheezing, and coughing up blood. They include medications and surgery that help reduce and destroy the growth of cancerous tumors in the lungs. They also involve therapies that focus on specific genetic mutations or alterations in cancer cells and stimulate the immune system to fight against the disease. At present, the growing prevalence of lung cancer on account of the increasing consumption of smoking products, rising pollution level, and unhealthy dietary patterns is catalyzing the demand for effective lung cancer therapeutics.
Small Cell Lung Cancer (SCLC)
A detailed breakup and analysis of the lung cancer therapeutics market based on the cancer type has also been provided in the report. This includes non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). According to the report, non-small cell lung cancer (NSCLC) accounted for the largest market share.
Lung cancer therapeutics refer to various treatment options used for managing and treating the symptoms of lung cancer, which include shortness of breath, chest pain, wheezing, and coughing up blood. They include medications and surgery that help reduce and destroy the growth of cancerous tumors in the lungs. They also involve therapies that focus on specific genetic mutations or alterations in cancer cells and stimulate the immune system to fight against the disease. At present, the growing prevalence of lung cancer on account of the increasing consumption of smoking products, rising pollution level, and unhealthy dietary patterns is catalyzing the demand for effective lung cancer therapeutics.
Lung Cancer Therapeutics Market Trends:
The rising awareness among individuals about the benefits of early diagnosis and treatment of cancer currently represents one of the key factors offering a favorable market outlook. Apart from this, the development of targeted therapies that offer personalized treatment options and improve patient outcomes are favoring market growth. Molecular testing and genetic profiling enable the identification of specific mutations and biomarkers in lung cancer cells. In line with this, the increasing use of nanomedicine to increase the efficient delivery of the anticancer drug to the affected tissues by enhancing the efficacy and reducing the side effects. Furthermore, the increasing use of immune checkpoint inhibitors (ICIs) as monotherapy or in combination with other therapies is creating a positive market outlook. Additionally, the rising adoption of combination therapies, which involve the simultaneous use of multiple treatment modalities, is strengthening the market growth. Besides this, the expanding utilization of liquid biopsies, which involve the analysis of circulating tumor deoxyribonucleic acid (DNA) and other biomarkers in blood samples, is driving the market. Liquid biopsies act as a non-invasive method of assessing tumor mutational status and treatment response, thereby enabling real-time monitoring and adjustment of therapy. Moreover, strategic collaborations between pharmaceutical companies, research institutions, and healthcare providers to develop innovative therapies and drugs are propelling market growth. Along with this, ongoing research and technological advancements in novel treatment modalities, drug delivery systems, and diagnostic tools for lung cancer are expected to stimulate market growth.Key Market Segmentation:
The publisher provides an analysis of the key trends in each segment of the global lung cancer therapeutics market, along with forecasts at the global, regional, and country levels from 2023-2028. The report has categorized the market based on therapy, cancer type, and distribution channel.Therapy Insights:
- Targeted Therapy
- Bevacizumab
- Dabrafenib/Trametinib
- Erlotinib Hydrochloride
- Osimertinib
- Others
- Immunotherapy
- Durvalumab
- Nivolumab
- Atezolizumab
- Pembrolizumab
- Radiation Therapy
- External Beam
- Internal Beam
- Systemic
- Chemotherapy
Cancer Type Insights:
Non-small Cell Lung Cancer (NSCLC)Small Cell Lung Cancer (SCLC)
A detailed breakup and analysis of the lung cancer therapeutics market based on the cancer type has also been provided in the report. This includes non-small cell lung cancer (NSCLC), and small cell lung cancer (SCLC). According to the report, non-small cell lung cancer (NSCLC) accounted for the largest market share.
Distribution Channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Competitive Landscape:
The report has also provided a comprehensive analysis of the competitive landscape in the global lung cancer therapeutics market. Detailed profiles of all major companies have been provided. Some of the companies covered include AbbVie Inc., Amgen Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company Limited, Eli Lilly and Company, GSK PLC, Merck & Co. Inc., Novartis AG, Pfizer Inc., Roche Holding AG, Takeda Pharmaceutical Company Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report:
- How has the global lung cancer therapeutics market performed so far, and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global lung cancer therapeutics market?
- What is the impact of each driver, restraint, and opportunity on the global lung cancer therapeutics market?
- What are the key regional markets?
- Which countries represent the most attractive lung cancer therapeutics market?
- What is the breakup of the market based on the therapy?
- Which is the most attractive therapy in the lung cancer therapeutics market?
- What is the breakup of the market based on the cancer type?
- Which is the most attractive cancer type in the lung cancer therapeutics market?
- What is the breakup of the market based on the distribution channel?
- Which is the most attractive distribution channel in the lung cancer therapeutics market?
- What is the competitive structure of the global lung cancer therapeutics market?
- Who are the key players/companies in the global lung cancer therapeutics market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Lung Cancer Therapeutics Market
6 Market Breakup by Therapy
7 Market Breakup by Cancer Type
8 Market Breakup by Distribution Channel
9 Market Breakup by Region
10 Drivers, Restraints, and Opportunities
12 Porters Five Forces Analysis
14 Competitive Landscape
Companies Mentioned
- AbbVie Inc.
- Amgen Inc.
- AstraZeneca Plc
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Daiichi Sankyo Company Limited
- Eli Lilly
- Company
- GSK PLC
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Roche Holding AG
- Takeda Pharmaceutical Company Limited
Methodology
LOADING...
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 145 |
Published | September 2023 |
Forecast Period | 2022 - 2028 |
Estimated Market Value ( USD | $ 27221.6 Million |
Forecasted Market Value ( USD | $ 50233 Million |
Compound Annual Growth Rate | 10.8% |
Regions Covered | Global |
No. of Companies Mentioned | 14 |